BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: El-hussien D, El-zaafarany GM, Nasr M, Sammour O. Chrysin nanocapsules with dual anti-glycemic and anti-hyperlipidemic effects: Chemometric optimization, physicochemical characterization and pharmacodynamic assessment. International Journal of Pharmaceutics 2021;592:120044. [DOI: 10.1016/j.ijpharm.2020.120044] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
Number Citing Articles
1 Rathod S, Arya S, Kanike S, Shah SA, Bahadur P, Tiwari S. Advances on nanoformulation approaches for delivering plant-derived antioxidants: A case of quercetin. Int J Pharm 2022;625:122093. [PMID: 35952801 DOI: 10.1016/j.ijpharm.2022.122093] [Reference Citation Analysis]
2 Bseiso EA, Abd El-Aal SA, Nasr M, Sammour OA, Abd El Gawad NA. Intranasally administered melatonin core-shell polymeric nanocapsules: A promising treatment modality for cerebral ischemia. Life Sci 2022;:120797. [PMID: 35841976 DOI: 10.1016/j.lfs.2022.120797] [Reference Citation Analysis]
3 Miao L, Liu C, Cheong MS, Zhong R, Tan Y, Rengasamy KRR, Leung SWS, Cheang WS, Xiao J. Exploration of natural flavones' bioactivity and bioavailability in chronic inflammation induced-type-2 diabetes mellitus. Crit Rev Food Sci Nutr 2022;:1-28. [PMID: 35821658 DOI: 10.1080/10408398.2022.2095349] [Reference Citation Analysis]
4 El-Gogary RI, Nasr M, Rahsed LA, Hamzawy MA. Ferulic acid nanocapsules as a promising treatment modality for colorectal cancer: Preparation and in vitro/in vivo appraisal. Life Sci 2022;298:120500. [PMID: 35341825 DOI: 10.1016/j.lfs.2022.120500] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
5 Adangale SC, Wairkar S. Potential therapeutic activities and novel delivery systems of chrysin-a nature’s boon. Food Bioscience 2022;45:101316. [DOI: 10.1016/j.fbio.2021.101316] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
6 Gao S, Siddiqui N, Etim I, Du T, Zhang Y, Liang D. Developing nutritional component chrysin as a therapeutic agent: Bioavailability and pharmacokinetics consideration, and ADME mechanisms. Biomed Pharmacother 2021;142:112080. [PMID: 34449320 DOI: 10.1016/j.biopha.2021.112080] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Stompor-Gorący M, Bajek-Bil A, Machaczka M. Chrysin: Perspectives on Contemporary Status and Future Possibilities as Pro-Health Agent. Nutrients 2021;13:2038. [PMID: 34198618 DOI: 10.3390/nu13062038] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
8 Nasr G, Greige-Gerges H, Elaissari A, Khreich N. Liposome Permeability to Essential Oil Components: A Focus on Cholesterol Content. J Membr Biol 2021;254:381-95. [PMID: 33939003 DOI: 10.1007/s00232-021-00180-3] [Reference Citation Analysis]
9 Ren T, Zheng X, Bai R, Yang Y, Jian L. Utilization of PLGA nanoparticles in yeast cell wall particle system for oral targeted delivery of exenatide to improve its hypoglycemic efficacy. Int J Pharm 2021;601:120583. [PMID: 33839225 DOI: 10.1016/j.ijpharm.2021.120583] [Reference Citation Analysis]
10 Zhang R, Zhang Y, Huang G, Xin X, Tang L, Li H, Lee KS, Jin BR, Gui Z. Chemical synthesis, inhibitory activity and molecular mechanism of 1-deoxynojirimycin–chrysin as a potent α-glucosidase inhibitor. RSC Adv 2021;11:38703-11. [DOI: 10.1039/d1ra07753h] [Reference Citation Analysis]